Liquidia gets FDA Fast Track for YUTREPIA in Raynaud's
Liquidia said the FDA granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for Raynaud’s phenomenon associated with systemic sclerosis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.